Register now to learn about a new option for relapsed or refractory follicular lymphoma

More Is Needed for Immunotherapy in Lung Cancer

Wednesday, July 31, 2019

Immunotherapy generated landmark change in the treatment of lung cancer, but there are still some pressing issues and unanswered questions that need to be addressed, according to Fred R. Hirsch, MD, PhD, executive director at the Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai (TCI) and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. 

Well immunotherapy is encouraging, but still we need a lot of work to improve the long-term effects. Even if we have very impressive, most recent 5-year survival data for monotherapy, and it might be even better with combination therapy, but what is the best combination? What is the sequencing of the combination? That is an area we need to work on in the future. 

We need solid clinical trials. We need to be sure we get biopsies from the patients before and after treatment to learn about sensitive mechanisms and resistant mechanisms. As I mentioned before, it is also in the future, important, in that case, it would be liquid biopsies during treatment to see if we can monitor the changes over time. 

Read more: Frontline Lung Cancer Treatment: What's the Best Strategy? 
Improving Immunotherapy Implementation in Community Practice

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.